Evidence map›Paper›PMID 31205740›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial.

Julie Falardeau, Allison Fryman, Rohan Wanchu, Gail H Marracci, Michele Mass, Lindsey Wooliscroft, Dennis N Bourdette, Charles F Murchison, William L Hills, Vijayshree Yadav

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Role of lipoic acid in multiple sclerosis.CNS neuroscience & therapeutics · 2022
    Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Rodent Models of Optic Neuritis.Frontiers in neurology · 2020
    Review
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Julie FalardeauOregon Health and Science University, USA.
Allison FrymanDepartment of Veterans Affairs, MS Center of Excellence - West, USA.
Rohan WanchuOregon Health and Science University, USA.
Gail H MarracciOregon Health and Science University, USA.
Michele MassOregon Health and Science University, USA.
Lindsey WooliscroftOregon Health and Science University, USA.
Dennis N BourdetteOregon Health and Science University, USA.
Charles F MurchisonDepartment of Biostatistics, University of Alabama at Birmingham, USA.
William L HillsOregon Health and Science University, USA.
Vijayshree YadavOregon Health and Science University, USA.ORCID https://orcid.org/0000-0001-8476-403X
Oregon Health & Science University · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipoic acid, an antioxidant, has beneficial effects in experimental acute optic neuritis and autoimmune encephalomyelitis. Optical coherence tomography can detect retinal nerve fiber layer thinning, representing axonal degeneration, approximately 3-6 months after acute optic neuritis.

objectiveTo determine whether lipoic acid is neuroprotective in acute optic neuritis.

methodsA single-center, double-blind, randomized, placebo controlled, 24-week trial. Intervention included 6 weeks of once daily lipoic acid (1200 mg) or placebo within 14 days of acute optic neuritis diagnosis. The primary outcome was the mean difference in affected eye retinal nerve fiber layer (RNFL) thickness from baseline to 24 weeks.

resultsWe enrolled 31 subjects (placebo n=16; lipoic acid n=15; average age 38.6 years (standard deviation (SD) 10.3)). Affected eye mean global RNFL thickness (µm) in the lipoic acid group decreased from 108.47 (SD 26.11) at baseline to 79.31 (SD 19.26) at 24 weeks. The affected eye RNFL in the placebo group decreased from 103.67 (SD 18.04) at baseline to 84.43 (SD 20.94) at 24 weeks. Unaffected eye RNFL thickness did not significantly change in either group over 24 weeks.

conclusionSix weeks of oral lipoic acid supplementation after acute optic neuritis is safe and well tolerated; however, because of insufficient recruitment, we could not conclude that lipoic acid treatment was neuroprotective in acute optic neuritis.

Indexed as

interventionlipoic acidMultiple sclerosisoptic neuritis

Identifiers

PMID31205740
PMCPMC6537072
OpenAlexW2945759883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.